Low-dose ibrutinib

Phase 2Small molecule

HHospital Universitario Dr. Jose E. Gonzalez

Low-dose ibrutinib is one of 67 small molecule programs targeting Chronic Graft Versus Host Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Graft Versus Host DiseaseActive, not recruiting

Multiple MyelomaActive, not recruiting

Chronic Graft Versus Host DiseasePhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Merck & Co.

Preclinical

—9

Low-dose ibrutinib

HHospital Universitario Dr. Jose E. Gonzalez

Phase 2

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Multiple Myeloma

NCT06758375

Clinical

Trials by Indication[1]

Chronic Graft Versus Host Disease1 trial

Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT05348096·13 enrolled

Multiple Myeloma1 trial

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT06758375·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Low-dose ibrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-dose ibrutinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-dose ibrutinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitario Dr. Jose E. Gonzalez company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHospital Universitario Dr. Jose E. Gonzalez

Low-dose ibrutinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Chronic Graft Versus Host Disease1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News